Biogen q4 earnings call
WebFeb 3, 2024 · Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? WebFeb 3, 2024 · For the fourth quarter Biogen generated approximately $2.7 billion in revenue, representing a decrease of 4% year-over-year, as we continued to experience the erosion of TECFIDERA revenue in the US, due to the impact of generic entry. Fourth quarter 2024 non-GAAP earnings were $3.39 a share.
Biogen q4 earnings call
Did you know?
WebINNOVENT BIOLOGICS, INC. : Nieuws en informatie aandeel INNOVENT BIOLOGICS, INC. 1801 N Mexican Stock Exchange WebFeb 15, 2024 · Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q4 2024 Results Conference Call February 15, 2024 8:00 AM ETCompany ParticipantsMike Hencke - Head, Investor …
WebApr 9, 2024 · April 9, 2024, 7:34 PM · 25 min read. Inventiva S.A. (NASDAQ: IVA) Q4 2024 Earnings Call Transcript March 30, 2024. Operator: Good day and thank you for standing by. Welcome to the Inventiva 2024 ... WebFeb 3, 2024 · EPS of $3.39 beats by $0.02 Revenue of $2.73B (-4.16% Y/Y) beats by $112.49M. The following slide deck was published by Biogen Inc. in conjunction with …
WebThe Motley Fool - Motley Fool Transcribing • 11h. Biogen (BIIB -3.49%) Q4 2024 Earnings Call Feb 15, 2024, 8:00 a.m. ET Prepared Remarks • Questions and Answers • Call Participants Prepared Remarks: Good …. Read more on … WebApr 12, 2024 · Biogen Stock Performance. NASDAQ:BIIB opened at $283.69 on Wednesday. The stock has a market cap of $40.99 billion, a P/E ratio of 13.55, a price-to-earnings-growth ratio of 2.46 and a beta of 0.19. The firm's fifty day simple moving average is $274.50 and its 200 day simple moving average is $278.54.
WebFeb 15, 2024 · Analyst Recommendations on BIOGEN INC. 04/06. RBC Capital Adjusts Biogen Price Target to $344 From $350, Maintains Outperform Rating. MT. 03/13. RBC Lifts Price Target on Biogen to $350 From $335, Cites More Confidence in Zuranolone.. MT. 02/27. RBC Lifts Price Target on Biogen to $335 From $333, Maintains Outperform …
WebFeb 7, 2024 · Biogen, Inc. (NASDAQ: BIIB) Q4 2024 earnings call dated Feb. 03, 2024 Corporate Participants: Mike Hencke — Director, Investor Relations Michel Vounatsos — Chief Executive Officer Alfred W. Sandrock — Executive Vice President Michael McDonnell — Executive Vice President Chief Financial Officer Analysts: Max Skor — Morgan … bis 80 material propertiesWebFeb 15, 2024 · SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System. bis 80 mechanical propertiesWebFeb 3, 2024 · Biogen Inc. ( NASDAQ: BIIB) reported fourth quarter 2024 earnings results today. Total revenue decreased 4% year-over-year to $2.73 billion. GAAP net income attributable to Biogen Inc. was $368 million, or $2.50 per share, compared to $358 million, or $2.32 per share, last year. Adjusted net income was $500 million, or $3.39 per share. bis 711 fillableWebFeb 15, 2024 · Q4 and Full Year 2024 Earnings Call Webcast. Feb 15, 2024 at 8:00 AM EST ... Biogen Reports Fourth Quarter and Full Year 2024 Results 310.3 KB. Q4 and Full Year 2024 Biogen Earnings Presentation 8.3 MB. Tools. Stockholder Communications. … bis80 plate thicknessWebFeb 15, 2024 · Biogen, Inc. (NASDAQ: BIIB) Q4 2024 earnings call dated Feb. 15, 2024Corporate Participants: Michael Hencke — Head of Investor Relations. Christopher … bis 6- membered cyclic carbonateWebFeb 3, 2024 · (RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:00 AM ET on February 3, 2024, to discuss Q4 21 earnings results. To access the live webcast, log on … bis888.ccWebFeb 3, 2024 · For the fourth quarter Biogen generated approximately $2.7 billion in revenue, representing a decrease of 4% year-over-year, as we continued to experience the erosion of TECFIDERA revenue in the US, due to the impact of generic entry. Fourth quarter 2024 non-GAAP earnings were $3.39 a share. We believe this performance … dark blue and orange background